Foresite Capital Management II’s 10x Genomics TXG Stock Holding History

Foresite Capital Management II’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$29.2M	Hold	708,528	–	–	100%	1
2023 Q2	$39.6M	Hold	708,528	–	–	100%	1
2023 Q1	$39.5M	Sell	708,528 -650,000	-48%	-$30.4M	100%	1
2022 Q4	$49.5M	Sell	1,358,528 -395,000	-23%	-$12.9M	100%	1
2022 Q3	$49.9M	Hold	1,753,528	–	–	100%	1
2022 Q2	$79.3M	Hold	1,753,528	–	–	100%	1
2022 Q1	$133M	Hold	1,753,528	–	–	100%	1
2021 Q4	$261M	Hold	1,753,528	–	–	99.34%	1
2021 Q3	$255M	Hold	1,753,528	–	–	90.72%	1
2021 Q2	$343M	Sell	1,753,528 -500,000	-22%	-$90.5M	92.37%	1
2021 Q1	$408M	Sell	2,253,528 -250,000	-10%	-$43.2M	93.76%	1
2020 Q4	$355M	Sell	2,503,528 -1,000,000	-29%	-$145M	93.6%	1
2020 Q3	$437M	Sell	3,503,528 -2,000,000	-36%	-$210M	95.05%	1
2020 Q2	$492M	Sell	5,503,528 -1,083,725	-16%	-$84.4M	96.63%	1
2020 Q1	$411M	Sell	6,587,253 -250,000	-4%	-$19.5M	95.85%	1
2019 Q4	$521M	Hold	6,837,253	–	–	85.84%	1
2019 Q3	$345M	Buy	+6,837,253	New	+$378M	72.85%	1

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Foresite Capital Management II's TXG Position: Q3 2023 in Review

Foresite Capital Management II held its 10x Genomics (TXG) position steady in Q3 2023 at 708,528 shares worth $29.2M. The position accounts for 100% of the portfolio, ranked #1.

Foresite Capital Management II first reported a position in TXG in Q3 2019 and has held it in 17 quarters since. The position peaked at $521M in Q4 2019. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

Foresite Capital Management II held 708,528 shares of 10x Genomics worth $29.2M as of Q3 2023.
Foresite Capital Management II left its 10x Genomics share count unchanged in Q3 2023.
10x Genomics made up 100% of Foresite Capital Management II's portfolio in Q3 2023, its #1 holding.
Foresite Capital Management II first reported a position in 10x Genomics in Q3 2019 and has held it in 17 quarters since.
Foresite Capital Management II's 10x Genomics position peaked at $521M in Q4 2019.
256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Foresite Capital Management II's 13F filing for Q3 2023, filed 13 Nov 2023.